NasdaqGS - Nasdaq Real Time Price USD
Relmada Therapeutics, Inc. (RLMD)
At close: November 6 at 4:00 PM EST
After hours: November 6 at 4:00 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
91,328.6020
103,702.2930
161,249.0760
125,703.4920
60,838.6730
Operating Income
-91,328.6020
-103,702.2930
-161,249.0760
-125,703.4920
-60,838.6730
Net Non Operating Interest Income Expense
4,599.5680
5,151.7040
2,659.4240
1,199.0770
1,399.2250
Other Income Expense
-34.4300
-241.1570
1,545.8290
-1,247.3940
-16.9460
Pretax Income
-86,763.4640
-98,791.7460
-157,043.8230
-125,751.8090
-59,456.3940
Net Income Common Stockholders
-86,763.4640
-98,791.7460
-157,043.8230
-125,751.8090
-59,456.3940
Diluted NI Available to Com Stockholders
-86,763.4640
-98,791.7460
-157,043.8230
-125,751.8090
-59,456.3940
Basic EPS
-2.87
-3.28
-5.30
-7.16
-3.81
Diluted EPS
-2.87
-3.28
-5.30
-7.16
-3.81
Basic Average Shares
30,126.1940
30,099.2030
29,628.6640
17,552.7380
15,594.2280
Diluted Average Shares
30,126.1940
30,099.2030
29,628.6640
17,552.7380
15,594.2280
Total Operating Income as Reported
-91,328.6020
-103,702.2930
-161,249.0760
-125,703.4920
-60,838.6730
Total Expenses
91,328.6020
103,702.2930
161,249.0760
125,703.4920
60,838.6730
Net Income from Continuing & Discontinued Operation
-86,763.4640
-98,791.7460
-157,043.8230
-125,751.8090
-59,456.3940
Normalized Income
-86,729.0340
-98,550.5890
-152,238.0460
-124,504.4150
-59,439.4480
Interest Income
4,599.5680
5,151.7040
2,659.4240
1,199.0770
1,399.2250
Net Interest Income
4,599.5680
5,151.7040
2,659.4240
1,199.0770
1,399.2250
EBIT
-91,328.6020
-103,702.2930
-161,249.0760
-125,703.4920
-60,838.6730
EBITDA
-91,328.6020
-103,702.2930
-161,249.0760
-125,702.2340
-60,834.9210
Reconciled Depreciation
--
--
--
1.2580
3.7520
Net Income from Continuing Operation Net Minority Interest
-86,763.4640
-98,791.7460
-157,043.8230
-125,751.8090
-59,456.3940
Total Unusual Items Excluding Goodwill
-34.4300
-241.1570
-4,805.7770
-1,247.3940
-16.9460
Total Unusual Items
-34.4300
-241.1570
-4,805.7770
-1,247.3940
-16.9460
Normalized EBITDA
-91,294.1720
-103,461.1360
-156,443.2990
-124,454.8400
-60,817.9750
12/31/2020 - 6/20/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
VANI Vivani Medical, Inc.
1.2600
0.00%
CLYM Climb Bio Inc
3.6500
+0.83%
MDNAF Medicenna Therapeutics Corp.
1.7000
-1.16%
2VSA.F Verastem, Inc.
3.5000
+0.57%
SLDB Solid Biosciences Inc.
6.14
+3.37%
GOSS Gossamer Bio, Inc.
0.8872
+1.11%
ALGS Aligos Therapeutics, Inc.
9.35
-4.88%
GBIO Generation Bio Co.
2.4000
+9.59%
GHRS GH Research PLC
8.72
+8.59%
NVCT Nuvectis Pharma, Inc.
8.15
+9.69%